Vivesto AB (VIVE.ST)
SEK 0.23
(-1.71%)
SEK 0.23
(-1.71%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | -1.29 Million SEK | -151.63% |
| 2021 | 2.51 Million SEK | 106.27% |
| 2020 | -40.12 Million SEK | 62.45% |
| 2019 | -106.85 Million SEK | -558.67% |
| 2018 | 23.29 Million SEK | -86.43% |
| 2017 | 171.68 Million SEK | 22.0% |
| 2016 | 140.72 Million SEK | 23.73% |
| 2015 | 113.73 Million SEK | 41.88% |
| 2014 | 80.16 Million SEK | -17.15% |
| 2013 | 96.75 Million SEK | 130.14% |
| 2012 | 42.04 Million SEK | 36.64% |
| 2011 | 30.76 Million SEK | 159.29% |
| 2010 | -51.89 Million SEK | -648.17% |
| 2009 | 9.46 Million SEK | -63.37% |
| 2008 | 25.84 Million SEK | 528.96% |
| 2007 | 4.1 Million SEK | 120.85% |
| 2006 | -19.7 Million SEK | -2745.26% |
| 2005 | -692.69 Thousand SEK | 64.86% |
| 2004 | -1.97 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 3.87 Million SEK | 30.78% |
| 2023 Q1 | 2.96 Million SEK | 327.87% |
| 2022 Q2 | 5.1 Million SEK | 66.61% |
| 2022 Q4 | -1.29 Million SEK | -133.79% |
| 2022 FY | -1.29 Million SEK | -151.63% |
| 2022 Q3 | 3.84 Million SEK | -24.7% |
| 2022 Q1 | 3.06 Million SEK | 21.78% |
| 2021 Q3 | 84.93 Million SEK | -2.02% |
| 2021 Q2 | 86.68 Million SEK | 17.03% |
| 2021 FY | 2.51 Million SEK | 106.27% |
| 2021 Q1 | 74.07 Million SEK | 284.58% |
| 2021 Q4 | 2.51 Million SEK | -97.04% |
| 2020 Q2 | 45 Million SEK | 142.12% |
| 2020 Q4 | -40.12 Million SEK | -201.5% |
| 2020 FY | -40.12 Million SEK | 62.45% |
| 2020 Q3 | 39.53 Million SEK | -12.15% |
| 2020 Q1 | -106.85 Million SEK | -263.34% |
| 2019 Q4 | 65.41 Million SEK | 5.12% |
| 2019 Q1 | 23.29 Million SEK | -70.2% |
| 2019 FY | -106.85 Million SEK | -558.67% |
| 2019 Q2 | 44.58 Million SEK | 91.38% |
| 2019 Q3 | 62.22 Million SEK | 39.58% |
| 2018 Q3 | 118.78 Million SEK | -29.24% |
| 2018 Q4 | 78.18 Million SEK | -34.17% |
| 2018 Q2 | 167.86 Million SEK | -2.22% |
| 2018 FY | 23.29 Million SEK | -86.43% |
| 2018 Q1 | 171.68 Million SEK | 51.1% |
| 2017 FY | 171.68 Million SEK | 22.0% |
| 2017 Q4 | 113.61 Million SEK | 63.71% |
| 2017 Q3 | 69.4 Million SEK | 114.21% |
| 2017 Q2 | 32.4 Million SEK | -76.98% |
| 2017 Q1 | 140.72 Million SEK | -0.62% |
| 2016 Q1 | 113.73 Million SEK | 29.49% |
| 2016 FY | 140.72 Million SEK | 23.73% |
| 2016 Q4 | 141.59 Million SEK | 7.68% |
| 2016 Q3 | 131.5 Million SEK | -14.52% |
| 2016 Q2 | 153.84 Million SEK | 35.26% |
| 2015 Q2 | -24.92 Million SEK | -131.1% |
| 2015 Q4 | 87.83 Million SEK | 108.15% |
| 2015 Q1 | 80.16 Million SEK | -1.68% |
| 2015 FY | 113.73 Million SEK | 41.88% |
| 2015 Q3 | 42.19 Million SEK | 269.26% |
| 2014 Q1 | 96.75 Million SEK | 575.93% |
| 2014 Q4 | 81.53 Million SEK | -30.82% |
| 2014 Q3 | 117.86 Million SEK | 35.61% |
| 2014 Q2 | 86.91 Million SEK | -10.18% |
| 2014 FY | 80.16 Million SEK | -17.15% |
| 2013 Q1 | 42.04 Million SEK | 2764.03% |
| 2013 FY | 96.75 Million SEK | 130.14% |
| 2013 Q3 | 94.14 Million SEK | 42.28% |
| 2013 Q4 | 14.31 Million SEK | -84.8% |
| 2013 Q2 | 66.17 Million SEK | 57.39% |
| 2012 Q1 | 30.76 Million SEK | 724.12% |
| 2012 Q4 | 1.46 Million SEK | -98.64% |
| 2012 FY | 42.04 Million SEK | 36.64% |
| 2012 Q2 | 76.64 Million SEK | 149.09% |
| 2012 Q3 | 107.63 Million SEK | 40.43% |
| 2011 Q3 | -4.62 Million SEK | 77.02% |
| 2011 Q2 | -20.11 Million SEK | 61.24% |
| 2011 Q4 | -4.93 Million SEK | -6.69% |
| 2011 FY | 30.76 Million SEK | 159.29% |
| 2011 Q1 | -51.89 Million SEK | 43.0% |
| 2010 Q4 | -91.04 Million SEK | -222.68% |
| 2010 FY | -51.89 Million SEK | -648.17% |
| 2010 Q3 | 74.2 Million SEK | 79.13% |
| 2010 Q2 | 41.42 Million SEK | 337.6% |
| 2010 Q1 | 9.46 Million SEK | 0.0% |
| 2009 FY | 9.46 Million SEK | -63.37% |
| 2008 FY | 25.84 Million SEK | 528.96% |
| 2007 FY | 4.1 Million SEK | 120.85% |
| 2006 FY | -19.7 Million SEK | -2745.26% |
| 2005 FY | -692.69 Thousand SEK | 64.86% |
| 2004 FY | -1.97 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 93.25% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 95.536% |
| BioGaia AB (publ) | -1.53 Billion SEK | 99.915% |
| Enzymatica AB (publ) | 17.73 Million SEK | 107.324% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | 77.278% |
| Gabather AB (publ) | -1.11 Million SEK | -16.502% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 107.345% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 97.673% |
| Nanexa AB (publ) | -61.13 Million SEK | 97.875% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 91.511% |
| ODI Pharma AB | -2.63 Million SEK | 50.756% |
| Orexo AB (publ) | 302.8 Million SEK | 100.429% |
| Probi AB (publ) | -275.85 Million SEK | 99.529% |
| Swedencare AB (publ) | 1.42 Billion SEK | 100.091% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.007% |
| Toleranzia AB | -17.45 Million SEK | 92.558% |